Zerlasiran sodium

Zerlasiran sodium, an apolipoprotein A (ApoA) synthesis reducer, is a small interfering RNA (siRNA) therapeutic developed for the treatment of cardiovascular diseases. By specifically targeting and silencing the messenger RNA (mRNA) responsible for the production of atherogenic proteins, zerlasiran aims to reduce the expression of these proteins and thereby mitigate the progression of atherosclerosis and other related conditions.

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Catalog

BRP-02777

Synonyms

SLN360 sodium; RNA, (Am-sp-(2'-deoxy-2'-fluoro)U-sp-Am-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Cm-sp-(2'-deoxy-2'-fluoro)C-sp-Gm), complex with RNA (Cm-Gm-Gm-Um-Am-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)G-(2'-deoxy-2'-fluoro)G-Am-Cm-Am-Gm-Am-Gm-Um-Um-sp-Am-sp-Um) 5'-[O-[21-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-9,9-bis[12-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-7-mercapto-7-oxido-2,6,8-trioxa-7-phosphadodec-1-yl]-16-mercapto-16-oxido-7,11,15,17-tetraoxa-16-phosphaheneicos-1-yl] hydroxy phosphate] (1:1), sodium salt

Molecular Weight

14155.81

Molecular Formula

C443H556F12N144Na38O277P40S10

Solubility

Soluble in DMSO.

Appearance

White to off-white solid

Storage

Store at -20 °C

Related CAS

2646703-64-0 (free acid)